Therapeutics: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)

Patient sample and mouse studies suggest inhibiting CXCL1-CXCR1/CXCR2 signaling could help treat prostate cancer in obese patients. CXCL1 was highly expressed in tumor samples from 19 of 21 obese prostate cancer patients, compared with 1 of 16 lean prostate cancer patients. In an obese mouse model of prostate cancer, tumor knockdown of CXCL1 decreased tumor growth, tumor vascularization, and adipose stromal cell infiltration into tumors compared with normal CXCL1 expression. Also in the model, the dual CXCR1/CXCR2 inhibitor reparixin decreased tumor growth compared with no treatment. Next steps include investigating the mechanisms that regulate CXCL1 expression in cancer cells...